HIV Prevention Research Study
Researchers at the University of Pennsylvania are conducting a study on HIV prevention for healthy adults.
Fast Facts
Adults Sexually Active with Partners Assigned Male at Birth
Not Living with HIV
Compensation
Provided up to $700
Conducted in
Philadelphia, PA
Study Background
Help researchers test a once-yearly injection that may prevent HIV.
Researchers at the University of Pennsylvania are inviting healthy adults to participate in a clinical research study sponsored by Gilead Sciences. The Purpose 365 Study is evaluating the safety and acceptability of lenacapavir (LEN), a medication already approved by the U.S. Food and Drug Administration (FDA) for treating HIV, but not yet approved for prevention.
This study aims to determine whether LEN, given once per year as an injection into the muscle, could serve as a new and convenient option for HIV prevention. Participants will help researchers better understand how this investigational approach compares to existing HIV prevention methods and may play an important role in shaping future care options.
Study Background
Help researchers test a once-yearly injection that may prevent HIV.
Researchers at the University of Pennsylvania are inviting healthy adults to participate in a clinical research study sponsored by Gilead Sciences. The Purpose 365 Study is evaluating the safety and acceptability of lenacapavir (LEN), a medication already approved by the U.S. Food and Drug Administration (FDA) for treating HIV, but not yet approved for prevention.
This study aims to determine whether LEN, given once per year as an injection into the muscle, could serve as a new and convenient option for HIV prevention. Participants will help researchers better understand how this investigational approach compares to existing HIV prevention methods and may play an important role in shaping future care options.
Additional Information
This study is being conducted to learn how safe and acceptable the investigational drug lenacapavir (LEN) is when used for HIV prevention in healthy adults.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Not living with HIV
- Have not had oral Lenacapavir in the past 90 days or injectable Lenacapavir in the past 18 months
- Could benefit from PrEP
- Cisgender men, TGW, TGM, cisgender women, and nonbinary individuals who have sex with partners assigned male at birth
- Generally healthy
Participation will last at least one year. During the first 12 months, participants will receive a single injection of the study drug and attend at least eight in-person study visits. These visits will include physical exams, blood draws, and other routine health assessments. Before enrollment, you’ll complete a phone interview to confirm eligibility.
Participants will receive at least $700 in total compensation for their time.
There is no cost for you to participate in our research study. The study site is located at 3535 Market Street, just one block from the 34th Street SEPTA Market-Frankford line station for easy transportation access.